Short answer · Medically reviewed summary · Last updated: 2026-04-06
Moyamoya disease was first described in the medical literature in 1957 by Japanese physicians Takeuchi and Shimizu, who initially identified it as bilateral hypoplasia of the internal carotid arteries. The Origin of the Name The term Moyamoya—Japanese for "puff of smoke"—was coined in 1969 by Suzuki and Takaku. This poetic but accurate name describes the hazy appearance of the small, compensatory collateral blood vessels that develop when the major arteries at the base of the brain become narrowed or blocked.
What is the history of Moyamoya?
History of Moyamoya: when and how it was discovered, and the milestones in research since, medically reviewed.
Moyamoya disease was first described in the medical literature in 1957 by Japanese physicians Takeuchi and Shimizu, who initially identified it as bilateral hypoplasia of the internal carotid arteries.
The Origin of the Name
The term Moyamoya—Japanese for "puff of smoke"—was coined in 1969 by Suzuki and Takaku. This poetic but accurate name describes the hazy appearance of the small, compensatory collateral blood vessels that develop when the major arteries at the base of the brain become narrowed or blocked. While initially thought to be a condition exclusive to the Japanese population, subsequent global research confirmed that Moyamoya is a worldwide phenomenon affecting diverse ethnic groups.
Evolution of Understanding and Treatment
Historically, the condition was frequently misdiagnosed as generalized atherosclerosis or inflammatory vasculitis. As neuroimaging technology evolved from invasive cerebral angiography to sophisticated MRI and MRA, clinicians gained the ability to visualize the delicate vascular changes of Moyamoya without surgical risk. Treatment milestones have shifted from conservative management to surgical revascularization, such as EDAS (encephaloduroarteriosynangiosis) and direct bypass procedures, which are now standard to restore blood flow to ischemic brain tissue.
Modern Insights and Advocacy
In recent years, the discovery of the RNF213 gene mutation has revolutionized our understanding of Moyamoya, moving the field toward a focus on genetic predisposition rather than purely environmental triggers. This genetic breakthrough has empowered patients, fueling a surge in advocacy and awareness. Today, communities like those on DiseaseMaps.org allow patients with Moyamoya to share their journeys, turning a once-obscure diagnosis into a well-recognized target for specialized neurosurgical care and global research collaboration.
Disclaimer: This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
References
- NIH Genetic and Rare Diseases Information Center (GARD)
- Orphanet: The portal for rare diseases and orphan drugs
- OMIM (Online Mendelian Inheritance in Man)
- Moyamoya Foundation
